Sugi Predict

Sugi Predict / Compounds / SCHEMBL724189

SCHEMBL724189

SCHEMBL724189

Cc1c(CBr)cccc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 7/20 0.41
▸ IDO1 P14902 2/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ PIK3CD O00329 2/20 0.38
▸ PIK3CB P42338 2/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ TAS2R14 Q9NYV8 1/20 0.37
▸ SCN8A Q9UQD0 1/20 0.37
▸ PIK3C2B O00750 1/20 0.37
▸ NOTUM Q6P988 1/20 0.36
▸ CTSS P25774 1/20 0.36
▸ CMA1 P23946 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30513592 1.00 P2RX7 (0.41) P2RX7IDO1CYP2D6SLC6A2SLC6A4
SCHEMBL10124833 0.85 P2RX7 (0.39) P2RX7IDO1CYP2D6SLC6A2SLC6A4
SCHEMBL28000643 0.85 P2RX7 (0.40) P2RX7IDO1CYP2D6SLC6A2SLC6A4
SCHEMBL31751977 0.82 GABRA1 (0.46) P2RX7IDO1CYP2D6SLC6A2SLC6A4
SCHEMBL11967099 0.82 GABRA1 (0.46) P2RX7IDO1CYP2D6SLC6A2SLC6A4
SCHEMBL18753207 0.82 IDO1 (0.41) P2RX7IDO1CYP2D6SLC6A2SLC6A4
SCHEMBL21283351 0.81 GABRA1 (0.52) P2RX7IDO1CYP2D6SLC6A2SLC6A4
SCHEMBL29427013 0.81 IDO1 (0.57) IDO1SLC6A2SLC6A4
SCHEMBL4527 0.81 IDO1 (0.57) IDO1SLC6A2SLC6A4
SCHEMBL737569 0.80 PDCD1 (0.48) P2RX7IDO1CYP2D6SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9156797-B2 Benzimidazole derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-10-13 — — US claimed
US-20150246889-A1 Benzimidazole Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC 2015-09-03 — — US claimed
WO-2025264837-A1 NAPHTHYRIDINE GPR52 MODULATORS AND METHODS OF USE THEREOF LIEBER INSTITUTE, INC. (US) 2025-12-26 — — WO disclosed
EP-4474017-A2 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-11 — — EP disclosed
EP-3837263-B1 NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN LA ROCHE (CH) 2024-07-03 — — EP disclosed
CN-116478154-A Quinuclidine derivative and preparation method and application thereof 北京大学宁波海洋药物研究院 2023-07-25 — — CN disclosed
CN-108368107-B Fused heterocyclic compounds as S1P modulators 艾伯维公司 2021-11-26 — — CN disclosed
CN-109311843-B Azabenzimidazole derivatives as PI3K beta inhibitors 詹森药业有限公司 2021-10-08 — — CN disclosed
EP-3472160-B1 BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-02-24 — — EP disclosed
US-10894793-B2 Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-01-19 — — US disclosed
EP-3472147-B1 AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-06-17 — — EP disclosed
US-7652013-B2 Inhibitors of stearoyl-CoA desaturase HOFFMAN-LA ROCHE INC. (US) 2010-01-26 — — US disclosed
WO-2009074487-A1 INHIBITORS OF STEAROYL-COA DESATURASE F. HOFFMANN-LA ROCHE AG (CH) 2009-06-18 — — WO disclosed
US-20090149466-A1 INHIBITORS OF STEAROYL-COA DESATURASE GILLESPIE PAUL 2009-06-11 — — US disclosed
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-04-23 — — US disclosed
US-20080262086-A1 SUBSTITUTED ANTHRANILIC ACIDS AUSPEX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2007-12-06 — — US disclosed
CN-1950375-A Glucocorticoid receptor modulator compounds and methods- utility LIGAND PHARM INC (US) 2007-04-18 — — CN disclosed
EP-1718653-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY Ligand Pharmaceuticals Inc. (US) 2006-11-08 — — EP disclosed
WO-2005082909-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY LIGAND PHARMACEUTICALS INCORPORATED (US) 2005-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10894793-B2 Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors PIK3CA, PIK3CD, PIK3CB P2RX7 39/4885IDO1 824/4885CYP2D6 1093/4885
US-20080262086-A1 SUBSTITUTED ANTHRANILIC ACIDS GLS, ASNS, REN P2RX7 3326/4885IDO1 1482/4885CYP2D6 59/4885
US-20090149466-A1 INHIBITORS OF STEAROYL-COA DESATURASE SCD, SCD5, FADS2 P2RX7 4843/4885IDO1 1459/4885CYP2D6 593/4885
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods NR3C1, NR3C2, MC2R P2RX7 936/4885IDO1 3384/4885CYP2D6 229/4885
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods NR3C1, NR3C2, MC2R P2RX7 936/4885IDO1 3384/4885CYP2D6 229/4885
US-20150246889-A1 Benzimidazole Derivatives As PI3 Kinase Inhibitors PI4KB, PIK3CD, PI4KA P2RX7 524/4885IDO1 1785/4885CYP2D6 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.